Pierce, MA
Albert Pierce, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20090088445 | Deazapurines useful as inhibitors of Janus kinases - The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 04-02-2009 |
20090176763 | Azaindoles useful as inhibitors of JAK and other protein kinases - The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 07-09-2009 |
20090325968 | Compositions Useful as Inhibitors of Protein Kinases - The present invention provides a compound of formula I: | 12-31-2009 |
20100160287 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES - The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 06-24-2010 |
20110008259 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using such CFTR modulators. | 01-13-2011 |
20110020377 | AMINOPYRIMIDINES USEFUL AS INHIBITORS OF PROTEIN KINASES - The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention. | 01-27-2011 |
20110118255 | PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JAK2 INHIBITORS - The present invention relates to compounds of formula (I) useful as selective inhibitors of JAK2 kinase. The invention also provides pharmaceutical acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various diseases, conditions or disorders. The invention also provides processes for preparing the compounds of the invention. | 05-19-2011 |
20120157429 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES - The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 06-21-2012 |
20120165307 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES - The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 06-28-2012 |
20120258958 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES - The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 10-11-2012 |
20120316186 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES - The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 12-13-2012 |
20130237516 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES - The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 09-12-2013 |
20130345197 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES - The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 12-26-2013 |
20140073653 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR - The present invention relates to compounds of formula IVA, formula IVB, or formula IVC, useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using such CFTR modulators. | 03-13-2014 |
20140171454 | Substituted Pyrrolo[2,3-d]pyrimidines as Inhibitors of Protein Kinases - The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 06-19-2014 |
20140221336 | COMPOUNDS USEFUL AS INHIBITORS OF JANUS KINASES - The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 08-07-2014 |
20140249138 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES - The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 09-04-2014 |
20140315931 | DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES - The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 10-23-2014 |
20140336171 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES - The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 11-13-2014 |
20150152103 | AZAINDOLES USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES - The present invention relates to inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders. | 06-04-2015 |
Albert C. Pierce, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20110172238 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS - Compounds represented by formula I: | 07-14-2011 |
20130157997 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS - Compounds represented by formula I: | 06-20-2013 |
20140243257 | BENZIMIDAZOLE ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS - Compounds represented by formula I: | 08-28-2014 |
Albert Charles Pierce, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20120040950 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE - The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 02-16-2012 |
20120202784 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE - The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 08-09-2012 |
20130281431 | DNA-PK INHIBITORS - The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 10-24-2013 |
20140038936 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE - The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 02-06-2014 |
20140045869 | DNA-PK INHIBITORS - The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 02-13-2014 |
20140275024 | DNA-PK INHIBITORS - The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 09-18-2014 |
20140275059 | DNA-PK INHIBITORS - The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 09-18-2014 |
20150111871 | DNA-PK INHIBITORS - The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. | 04-23-2015 |
Allen Richard Pierce, Acton, MA US
Patent application number | Description | Published |
---|---|---|
20100204124 | Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members - The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily. According to the invention, an exemplary bioactive agent is BMP-7 The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the site of intravascular delivery of the bioactive agent. | 08-12-2010 |
20130316949 | Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members - The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily. According to the invention, an exemplary bioactive agent is BMP-7 The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the site of intravascular delivery of the bioactive agent. | 11-28-2013 |
20140187473 | Compositions and Methods for Minimally-Invasive Systemic Delivery of Proteins Including TGF-Beta Superfamily Members - The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily. According to the invention, an exemplary bioactive agent is BMP-7. The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the site of intravascular delivery of the bioactive agent. | 07-03-2014 |
20140342976 | COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-BETA SUPERFAMILY MEMBERS - The present invention is directed to methods and compositions for systemic delivery of minimally-soluble bioactive agents such as, but not limited to, proteins of the TGF-β superfamily. According to the invention, an exemplary bioactive agent is BMP-7 The invention further provides for minimally-invasive systemic treatment of skeletal disorders such as osteoporosis as well as minimally-invasive systemic treatment of injured or diseased non-mineralized tissues and organs such kidneys. Practice of the invention eliminates adverse side effects at the site of intravascular delivery of the bioactive agent. | 11-20-2014 |
Brian G. Pierce, Wayland, MA US
Patent application number | Description | Published |
---|---|---|
20140341809 | High-Affinity DMF5 T Cell Receptor (TCR) Variants - High-affinity variants of the DMF5 TCR, and methods of use thereof for the treatment and imaging of cancer in a patient. | 11-20-2014 |
Brian Gregory Pierce, Wayland, MA US
Patent application number | Description | Published |
---|---|---|
20110052621 | PCSK9 VACCINE - The present invention relates to the provision of novel immunogens comprising an antigenic PCSK9 peptide linked to an immunogenic carrier for the prevention, treatment or alleviation of PCSK9-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine. | 03-03-2011 |
20130078270 | HER-2 PEPTIDES AND VACCINES - The present invention provides (a) isolated immunogenic HER-2 peptides capable of inducing immune responses against human HER-2 receptor; (b) isolated nucleic acid molecules encoding an isolated immunogenic HER-2 peptide; (c) plasmid constructs comprising a nucleic acid molecule encoding an isolated immunogenic HER-2 peptide; (d) vaccine compositions comprising an isolated immunogenic HER-2 peptide (e) vaccine compositions comprising an isolated nucleic acid molecule encoding an isolated immunogenic HER-2 peptide; and (f) methods of treating or preventing cancer, inhibiting abnormal cell proliferation, or eliciting an immune response against HER-2 protein in a mammal using (1) an isolated immunogenic HER-2 peptide, (2) nucleic acid molecule encoding an isolated immunogenic HER-2 peptide, or (3) a composition comprising an isolated immunogenic HER-2 peptide, or composition comprising a nucleic acid molecule encoding an isolated immunogenic HER-2 peptide. | 03-28-2013 |
20130295110 | PROSTATE-ASSOCIATED ANTIGENS AND VACCINE-BASED IMMUNOTHERAPY REGIMENS - The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer. | 11-07-2013 |
20150246106 | PROSTATE-ASSOCIATED ANTIGENS AND VACCINE-BASED IMMUNOTHERAPY REGIMENS - The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer. | 09-03-2015 |
Brian Gregory Pierce, Marblehead, MA US
Patent application number | Description | Published |
---|---|---|
20150098957 | PCSK9 VACCINE - The present invention relates to the provision of novel immunogens comprising an antigenic PCSK9 peptide linked to an immunogenic carrier for the prevention, treatment or alleviation of PCSK9-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine. | 04-09-2015 |
Cori Pierce, Gloucester, MA US
Patent application number | Description | Published |
---|---|---|
20120226096 | VENTRICULAR CUFF - In one general aspect, an implant includes a cuff defining an opening configured to receive a cannula coupled to a heart pump. The implant includes a coupling mechanism having a first position and a second position, the cuff being uncoupled from the cannula in the first position and the coupling mechanism coupling the cuff to the cannula in the second position. The implant includes a locking mechanism configured to secure the coupling mechanism in the second position, and the locking mechanism is configured to be moved to a locked position after the coupling mechanism is in the second position. | 09-06-2012 |
Cori Pierce, Wakefield, MA US
Patent application number | Description | Published |
---|---|---|
20150335802 | VENTRICULAR CUFF - In one general aspect, an implant includes a cuff defining an opening configured to receive a cannula coupled to a heart pump. The implant includes a coupling mechanism having a first position and a second position, the cuff being uncoupled from the cannula in the first position and the coupling mechanism coupling the cuff to the cannula in the second position. The implant includes a locking mechanism configured to secure the coupling mechanism in the second position, and the locking mechanism is configured to be moved to a locked position after the coupling mechanism is in the second position. | 11-26-2015 |
Cori G. Pierce, Wakefield, MA US
Patent application number | Description | Published |
---|---|---|
20140067057 | VENTRICULAR CUFF - In one general aspect, a cuff for attachment to a heart includes an attachment component configured to engage a blood pump to attach the cuff to the blood pump and a sewing ring for attachment to the heart. The sewing ring is coupled to the attachment component, and the attachment component and the sewing ring each define a central opening configured to admit an inflow cannula of a blood pump. The sewing ring comprises a member that provides rigidity to flatten a portion of a myocardium of the heart when the cuff is attached to the heart. | 03-06-2014 |
20150273124 | Ventricular Cuff - In one general aspect, a cuff for attachment to a heart includes an attachment component configured to engage a blood pump to attach the cuff to the blood pump and a sewing ring for attachment to the heart. The sewing ring is coupled to the attachment component, and the attachment component and the sewing ring each define a central opening configured to admit an inflow cannula of a blood pump. The sewing ring comprises a member that provides rigidity to flatten a portion of a myocardium of the heart when the cuff is attached to the heart. | 10-01-2015 |
20160051738 | VENTRICULAR CUFF - In one general aspect, a cuff for attachment to a heart includes an attachment component configured to engage a blood pump to attach the cuff to the blood pump and a sewing ring for attachment to the heart. The sewing ring is coupled to the attachment component, and the attachment component and the sewing ring each define a central opening configured to admit an inflow cannula of a blood pump. The sewing ring comprises a member that provides rigidity to flatten a portion of a myocardium of the heart when the cuff is attached to the heart. | 02-25-2016 |
Cori Grace Pierce, Melrose, MA US
Patent application number | Description | Published |
---|---|---|
20160121033 | Apical Connectors and Instruments for Use in a Heart Wall - The present disclosure provides an apical connector for use in a heart wall. The apical connector may include a port defining an aperture therethrough, an anchoring device extending distally from the port and configured for advancing at least partially through the heart wall, and a cannula configured for advancing through the aperture of the port and at least partially through the heart wall. The cannula may include a locking tab configured to engage the port and lock the cannula with respect to the port. | 05-05-2016 |
Glenn Pierce, Cambridge, MA US
Patent application number | Description | Published |
---|---|---|
20130171175 | Factor IX Polypeptides and Methods of Use Thereof - The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells. | 07-04-2013 |
20130202595 | Factor IX Polypeptides and Methods of Use Thereof - The present invention provides methods of administering Factor IX; methods of administering chimeric and hybrid polypeptides comprising Factor IX; chimeric and hybrid polypeptides comprising Factor IX; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells. | 08-08-2013 |
20140370035 | METHODS OF REDUCING IMMUNOGENICITY AGAINST FACTOR VIII IN INDIVIDUALS UNDERGOING FACTOR VIII THERAPY - The present disclosure provides methods of administering chimeric and hybrid Factor VIII (FVIII) polypeptides comprising FVIII and Fc to subjects at risk of developing inhibitory FVIII immune responses, including anti-FVIII antibodies and/or cell-mediated immunity. The administration is sufficient to promote coagulation and to induce immune tolerance to FVIII. The chimeric polypeptide can comprise full-length FVIII or a FVIII polypeptide containing a deletion, e.g., a full or partial deletion of the B domain. | 12-18-2014 |
20150252345 | Methods of Using FIX Polypeptides - The present invention provides methods of administering long-acting Factor IX; methods of administering long-acting, chimeric and hybrid polypeptides comprising Factor IX; and methods of producing such chimeric and hybrid polypeptides using cells. | 09-10-2015 |
Jacqueline W. Pierce, Wellesley, MA US
Patent application number | Description | Published |
---|---|---|
20090304594 | Methods for Predicting Treatment Response Based On the Expression Profiles of Protein and Transcription Biomarkers - The invention disclosed herein describes novel biomarkers useful for risk assessment, screening, prognosis and selection and monitoring of therapy for HDAC mediated cell proliferative disorders. In particular, the invention provides the identities of three particular proteins whose expression patterns are strongly predictive of a particular patient's treatment outcome, e.g., non-responsiveness to SAHA. The expression profile, or pattern, whether embodied in nucleic acid expression, protein expression, or other expression formats will find use in identifying and selecting patients afflicted with a particular HDAC mediated cancer who are likely to be non-responsive to SAHA-based therapy and thus candidates for other treatments. | 12-10-2009 |
James Pierce, Waltham, MA US
Patent application number | Description | Published |
---|---|---|
20140271233 | MODULAR PUMP PLATFORM - A modular pump platform includes a pump head module, a pump motor module, an electronics module and a separable tray. The pump motor module includes a pump motor having a rotary output removably coupled to a crank shaft of the pump head, the pump motor being one of multiple types of pump motors, and the pump motor module being detachably connected to the pump head module. The electronics module includes an electronic control circuit configured control operation of the pump motor, the electronic control circuit being one of multiple types of electronic control circuits corresponding to the types of pump motors. Each of the pump head module, the pump motor module and the electronics module is detachably connected to the separable tray. At least the pump motor module is interchangeable with another pump motor module comprising a pump motor of another type. | 09-18-2014 |
20140301879 | Angular Synchronization of Stationary and Orbiting Plate Scroll Blades in a Scroll Pump Using a Metallic Bellows - Parts of a pump head of a scroll pump facilitate an assembly process in which the stationary and orbiting scroll blades of the pump are angularly aligned or synchronized with one another. A metallic bellows of the pump head provides a primary means of synchronizing the stationary and orbiting scroll blades. The assembly process may be carried out using a fixture configured to be mountable to an assemblage including the bellows and the orbiting plate scroll. The fixture has a reference feature, and the orbiting plate scroll or the frame has another reference feature that can be aligned with the reference feature of the fixture, in the circumferential direction of the bellows, during the course of the assembly process. | 10-09-2014 |
Karen Pierce, Action, MA US
Patent application number | Description | Published |
---|---|---|
20100167324 | Quantitative Assays for Ras p21 in Body Fluids - The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitatiing total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy. | 07-01-2010 |
Karen Pierce, Acton, MA US
Patent application number | Description | Published |
---|---|---|
20140093890 | QUANTITATIVE ASSAYS FOR RAS P21 IN BODY FLUIDS - The present invention is directed to the detection and quantification of total ras p21 in body fluids, particularly serial changes of total ras p21 levels in a subject's body fluids. Further, the invention is directed to detecting and quantitating total ras p21 in conjunction with one or more other proteins, such as, oncoproteins, angiogenic factors, tumor markers, inhibitors, growth factor receptors, metastasis proteins, and tumor suppressors. The disclosed methods are diagnostic/prognostic for preneoplastic/neoplastic diseases, and useful to select therapies for patients with preneoplastic/neoplastic diseases. The disclosed methods are further useful to monitor the status of a patient's preneoplastic/neoplastic disease, and/or to monitor how a patient is responding to an anticancer therapy. | 04-03-2014 |
Kenneth Pierce, Natick, MA US
Patent application number | Description | Published |
---|---|---|
20080280292 | Late-PCR - A non-symmetric polymerise chain reaction (PCR) amplification method employing a limiting primer in low concentration whose concentration-adjusted melting point at least equals, and preferably exceeds, that of the excess primer, the latter in turn not being more than 25° C. below the melting temperature of the amplicon. Assays employing such amplification and labeled hybridization probes, including assays that include a detection step following primer extension or a low-temperature probe, or both. Kits for performing such assays and primer or primer-and-probe sets for performing the foregoing amplifications and assays. | 11-13-2008 |
20120040352 | Primers, probes and methods for nucleic acid amplification - Homogenous detection during or following PCR amplification, preferably LATE-PCR, utilizing fluorescent DNA dye and indirectly excitable labeled primers and probes, improves reproducibility and quantification. Low-temperature homogeneous detection during or following non-symmetric PCR amplification, preferably LATE-PCR, utilizing fluorescent DNA dye and indirectly excitable labeled mismatch-tolerant probes permits analysis of complex targets. Sequencing sample preparation methods following LATE-PCR amplifications reduce complexity and permit “single-tube” processing. | 02-16-2012 |
20120202203 | SINGLE PROBE, MULTIPLE TEMPERATURE, NUCLEIC ACID DETECTION METHODS, KITS, AND COMPOSITIONS - Provided herein are methods, kits, and compositions related to nucleic acid detection assays that allow discrimination of multiple target sequences with a single probe. In particular, provided herein are methods kits, and compositions that include single-probe target sequence discrimination where different target amplicons may have identical probe hybridization sequences by employing multiple temperature end-point signal probe detection. Also provided herein are methods, kits, and compositions for distinguishing between two or more target amplicons using multiple-temperature end-point probe detection. In certain embodiments, asymmetric PCR amplification methods are employed (e.g., LATE-PCR amplification). | 08-09-2012 |
20120208191 | STAPHYLOCOCCUS DETECTION ASSAYS - Provided herein are methods, kits, and compositions related to nucleic acid detection that allow the detection and discrimination of various | 08-16-2012 |
20130095479 | PRIMERS, PROBES AND METHODS FOR NUCLEIC ACID AMPLIFICATION - Homogenous detection during or following PCR amplification, preferably LATE-PCR, utilizing fluorescent DNA dye and indirectly excitable labeled primers and probes, improves reproducibility and quantification. Low-temperature homogeneous detection during or following non-symmetric PCR amplification, preferably LATE-PCR, utilizing fluorescent DNA dye and indirectly excitable labeled mismatch-tolerant probes permits analysis of complex targets. Sequencing sample preparation methods following LATE-PCR amplifications reduce complexity and permit “single-tube” processing. | 04-18-2013 |
20130210656 | LATE-PCR - A non-symmetric polymerise chain reaction (PCR) amplification method employing a limiting primer in low concentration whose concentration-adjusted melting point at least equals, and preferably exceeds, that of the excess primer, the latter in turn not being more than 25° C. below the melting temperature of the amplicon. Assays employing such amplification and labeled hybridization probes, including assays that include a detection step following primer extension or a low-temperature probe, or both. Kits for performing such assays and primer or primer-and-probe sets for performing the foregoing amplifications and assays. | 08-15-2013 |
20140206564 | REAGENTS FOR IMPROVING PCR ACCURACY - Provided herein are reagents for improving PCR accuracy. | 07-24-2014 |
Kenneth A. Pierce, Holyoke, MA US
Patent application number | Description | Published |
---|---|---|
20090214012 | ADVANCED PAYMENT FOR TELEPHONE SERVICES - A method of providing telephone services includes receiving an advanced payment. The advanced payment corresponds to a fixed time interval of telephone service spanning at least one day. The method also includes activating service to a mobile device for the fixed time interval and collecting a plurality of call data. | 08-27-2009 |
Kenneth E. Pierce, Natick, MA US
Patent application number | Description | Published |
---|---|---|
20110311971 | RT-LATE-PCR - An assay comprising more than one primer pair and more than one detection probe, a low copy number synthetic amplicon corresponding to each of the primer pairs. The assay can detect and distinguish between various sub-types and strains of an influenza virus using any suitable nucleic acid amplification technique. Related kits and methods are also described. | 12-22-2011 |
20130203626 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID BASED DIAGNOSTIC ASSAYS FOR VARIABLE SEQUENCE TARGETS - The present invention relates to compositions and methods for nucleic acid based diagnostic assays. In particular, the present invention provides primers for asymmetric PCR and other amplification modalities. In some embodiments, the present invention provides multiple primers for amplification of related nucleic acid targets in a single reaction. | 08-08-2013 |
20150148252 | MULTIPLEX TARGET DETECTION ASSAY - Provided herein are reagents and kits for detection of multiple target sequences in a single-tube, single-color assay, and methods of use thereof. In particular, multiplex assays are provided for the detection of | 05-28-2015 |
Mark D. Pierce, Kingston, MA US
Patent application number | Description | Published |
---|---|---|
20140336838 | Resource Control System With Local Reallocation - The invention provides a means for allowing an end user to determine how a finite amount of a measurable resource is allocated among the various balanceable and feature zones of control defined within the overall measurable resource control system, and which can be implemented using a wide variety of hardware/components. A control program allows the end user unprecedented flexibility and control to determine how the resource is allocated among the various zones or types of resource use within the application, as long as the total resource consumed does not exceed the predetermined/predefined total maximum allowable resource. When the end user adjusts a feature or balanceable zone level, the control program adjusts the other balanceable zones based on predefined algorithms, when necessary, to ensure that the maximum measurable resource consumed by the system does not exceed the predetermined/predefined overall maximum resource allocation. The invention is scalable and can be infinitely nested. | 11-13-2014 |
Michael Pierce, Canton, MA US
Patent application number | Description | Published |
---|---|---|
20100057743 | WEB-BASED SERVICES FOR QUERYING AND MATCHING LIKES AND DISLIKES OF INDIVIDUALS - A method for centrally providing a profile of a user's degree of preference for one or more items across categories in a plurality of domains of interest in a taxonomy of preferences is described. In one embodiment, the method includes identifying a user's degree of preference for an item from a plurality of indicators. The user's degree of preference for the item is associated with a category in a domain of interest and is stored in a profile of the user. In another embodiment, the profile identifies preferences of the user in a taxonomy of preferences across categories in a plurality of domains of interest. | 03-04-2010 |
20130254234 | WEB-BASED SERVICES FOR QUERYING AND MATCHING LIKES AND DISLIKES OF INDIVIDUALS - A method for centrally providing a profile of a user's degree of preference for one or more items across categories in a plurality of domains of interest in a taxonomy of preferences is described. In one embodiment, the method includes identifying a user's degree of preference for an item from a plurality of indicators. The user's degree of preference for the item is associated with a category in a domain of interest and is stored in a profile of the user. In another embodiment, the profile identifies preferences of the user in a taxonomy of preferences across categories in a plurality of domains of interest. | 09-26-2013 |
20150334205 | WEB-BASED SERVICES FOR QUERYING AND MATCHING LIKES AND DISLIKES OF INDIVIDUALS - A method for centrally providing a profile of a user's degree of preference for one or more items across categories in a plurality of domains of interest in a taxonomy of preferences is described. In one embodiment, the method includes identifying a user's degree of preference for an item from a plurality of indicators. The user's degree of preference for the item is associated with a category in a domain of interest and is stored in a profile of the user. In another embodiment, the profile identifies preferences of the user in a taxonomy of preferences across categories in a plurality of domains of interest. | 11-19-2015 |
Philip R. Pierce, South Yarmouth, MA US
Patent application number | Description | Published |
---|---|---|
20140116077 | Solar auxiliary power systems for vehicles - An integrated truck and trailer power system comprises auxiliary power generation and storage devices mounted on a trailer, such as an array of solar panels mounted on the roof of the trailer and a storage battery mounted on the trailer, and switching devices for controlling flow of power there between and to an electrically powered HVAC system of the truck, whereby the truck can be maintained at a comfortable temperature by supply of power stored by the auxiliary power storage device. | 05-01-2014 |
Richard Pierce, Plymouth, MA US
Patent application number | Description | Published |
---|---|---|
20090068412 | POLYURETHANE UPHOLSTERY - Products and methods directed to multilayer upholstery are disclosed. Such upholsteries can be used as a furniture covering or in other covering applications. In many instances, the multilayer upholstery comprises three layers: a clear, cross-linked urethane layer, a textile layer and a polymeric layer between and coupled to the clear and textile layers. Additionally, the multilayer upholstery can contain a solid color or printed pattern. The printed pattern can be derived from a printed textile surface or a print film disposed as one of the layers. Methods for modifying the layers to yield antimicrobial properties, chemical resistance and adhesive bonding between layers are also disclosed. | 03-12-2009 |
20110171864 | Protective laminates - Protective laminates are provided that include (a) a layer that is breathable and highly impermeable to chemicals to a degree that is subject to reduction upon flexing of the highly impermeable layer alone; and (b) a breathable non-textile layer attached to the highly impermeable layer, the non-textile layer mitigating the reduction in the impermeability of the highly impermeable layer if the laminate is flexed. The laminates may, for example, be attached to textiles and used in protective fabrics. | 07-14-2011 |
Robert Pierce, Wrentham, MA US
Patent application number | Description | Published |
---|---|---|
20080221501 | Systems and Methods for Reducing Intraocular Pressure - The present invention provides systems and methods for reducing intraocular pressure, thereby to treat glaucoma and other disorders. The systems of the present invention include a shunt insertable across the clear cornea and a delivery device for inserting the shunt in the transcorneal position. The shunt has a body with a head at one end and a foot at the opposite end, and a channel therethrough permitting the passage of aqueous humor from the anterior chamber to the external surface of the cornea. A removable filter is positioned within the channel to regulate aqueous humor outflow and to resist the incursion of microorganisms. | 09-11-2008 |